Influence of TP53 mutation on efficacy and survival in advanced EGFR-mutant non-small cell lung cancer patients treated with third-generation EGFR tyrosine kinase inhibitors
MEDCOMM(2024)
Key words
non-small-cell lung cancer,targeted therapy,third-generation EGFR tyrosine kinase inhibitors,TP53 comutation
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined